

■ TEL : 022 - 3001 5888 ■ FAX : 022 - 2405 7708

E-Mail : info@naxparlab.com
 Visit us at: www.naxparlab.com

■ GIN No. ; L36912MH1982PLC027925

Parnax Lab Ltd.

(Formerly Known as Krishna Deep Trade & Investment Ltd.)

114, BLDG. NO. 8, JOGANI IND. COMPLEX, SIGN-CHUNABHATTI, MUMBAI - 400 022, INDIA

Date: 14.11.2018

To,
Department of Corporate Service (DCS-CRD),
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400001

Sub: Submission of Un-Audited Standalone Financial Results for quarter and half year ended 30th September. 2018 in pursuance of Regulation 33 of Listing Obligation and Disclosure Requirement, 2015.

Ref.: Parnax Lab Limited, Script Code- 506128

Dear Sir.

Kindly find enclosed herewith the following:

 A Copy of Standalone & Consolidated Un-Audited Financial results with Limited Review Report of the Company for the quarter and year ended 30th September, 2018;

Kindly take on record and acknowledge receipt of the same.

Thanking You,

Yours faithfully,

FOR PARNAX LAB LIMITED

Bhoomi Thakkar

Blood

Company Secretary & Compliance Officer

Encl: As above

LADHA SINGHAL & ASSOCIATES

CHARTERED ACCOUNTANTS

To
The Board of Directors,
Parnax Lab Limited,
114, Building No. 8,
Jogani Industrial Complex,
Chunabhatti, Mumbai – 400 022

- 1. We have reviewed the unaudited standalone financial results of **Parnax Lab Limited** ("the company") for the quarter and half year ended 30th September, 2018 which are included in the accompanying "Statement of Unaudited Standalone Financial Result for the quarter and half year ended 30th September, 2018" together with the relevant notes thereon ("the Statement"). The Statement has been prepared by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. The Statement is the responsibility of the company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principal laid down in Indian Accounting Standard for Interim Financial Reporting (IndAS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
- 2. We conducted our review in accordance with the standards on Review Engagement (SRE) 2410 'Review on Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than as audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards and other accounting principals generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Discloser Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ladha Singhal and Associates

Chartered Accountants

(FRN: 120241W)

(Vinod Ladha)

Partner

M. No.: 104151

Place:Mumbai

Dated:14th November, 2018

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022.

Tel: 022 - 3001 5666, Fax: 2405 7708, Email: info@naxparlab.com, Website: www.naxparlab.com

CIN:-L36912MH1982PLC027925

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30.09.2018

(Rs. in Lakhs)

S.	Particulars	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
No.		Current	Previous	Correspondi		Correspondi	Addited
		Quarter	Quarter	ng Quarter	Current Half	na Half Voor	Year Ended
		Ended	ended	Ended	Year Ended	Ended	31.03.2018
		30.09.2018	30.06.2018	30.09.2017	30.09.2018	30.09.2017	01.00.2010
ı	Revenue from Operations	196.51	172.62	129.94	369.13	240.99	580.31
11	Other Income	19.66	5.16	2.65	24.82	3.92	34.83
III	Total Revenue (I+II)	216.17	177.78	132.59	393.95	244.91	615.14
IV	Expenses						
	a) Cost of Material Consumed	78.25	59.72	45.93	137.97	57.10	207.00
	b) Purchase of Stock in trade	23.30	29.12	15.80	52.42	42.27	64.89
+	c) Changes in inventories of finished goods, Work in progress and stock in trade	-	-	-		-	
	d) Employee benefit expenses	11.19	9.94	10.42	21.13	61.83	88.94
	e) Finance Cost	25.41	28:14	30.37	53.55	67.04	129.73
	f) Depreciation and amortisation expenses	1.18	1.25	12.04	2.43	23.95	44.11
	g) Other expenses	78.09	61.12	40.19	139.21	88.18	204.73
	h) Impairment of assets classified as held for disposal						123.40
	Total Expenses (IV)	217.42	189.29	154.75	406.71	340.37	862.80
V	Profit/(loss) before exceptional items and tax (III-IV)	(1.25)	(11.51)	(22.16)	(12.76)	(95.46)	(247.66)
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit/(loss) Before Tax (V-VI)	(1.25)	(11.51)	(22.16)	(12.76)	(95.46)	(247.66)
VIII	Tax expense						
	a) Current Tax	-	-	-	-	-	-
	b) Deferred Tax	-	-	-	-	-	(7.66)
	c) Short(Excess) Prov for Tax for Earlier Years						0.02
IX	Profit/ (Loss) for the period (VII-VIII)	(1.25)	(11.51)	(22.16)	(12.76)	(95.46)	(240.02)
X	Other Comprehensive Income					- 1 - 1 - 2	
	A. (i) Items that will not be reclassified to profit or loss		-			-	0.29
	(ii) Income tax relating to items that will not be reclassified to profit or loss		-	-		-	-
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XI	Total Other Comprehensive Income for the period	-	-		-	-	0.29
	Total Comprehensive Income comprising profit & other comprehensive						NO.
XII	income for the period (VIII+IX)	•	-	-	-	-	(239.73)
XIII	Paid-up equity share capital (Face Value of the share Rs. 10)	850.49	850.49	850.49	850.49	850.49	850.49
XIV	Earning per equity share (Not Annualised)						
	(1) Basic	(0.01)	(0.14)	(0.26)	(0.15)		(2.82)
	(2) Diluted	(0.01)	(0.14)	(0.26)	(0.15)	(1.12)	(2.82)

Notes-

1	The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 14, 2018			
2	The Statutory Auditors have carried out a Limited Review of the above financial results of the Company for the quarter and half year ended September 30, 2018			
3	EPS for quarter ended is on non annualised basis.			
4	The Company is dealing into one segment : Dealing in Pharmaceutical Formulations			
5	Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.			

Place : Mumbai Date : 14-11-2018 By Order of the Board For Parnax Lab Limited

Prakash M Shah Whole Time Director & CEO

Mumbai)

DIN NO: 00440980

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022. Tel : 022 - 3001 5666, Fax : 2405 7708, Email : info@naxparlab.com, Website : www.naxparlab.com CIN:-L36912MH1982PLC027925

Statement of Assets and Liabilities as at 30.09.2018

	·	(Rs. in Lac		
		Standalone		
0 N-	D. C. L.	Unaudited	Unaudited	Audited
S. No.	Particulars ASSETS	30.09.2018	30.09.2017	31.03.2018
1	Non-Current Assets		**	
(a)	Property, plant and equipment	50.70	000.40	00.00
(b)	Capital work-in-progress	59.73	622.12	62.06
(c)	Investment in Subsidiaries	998.00	1,009.35	998.00
(d)	Goodwill	990.00	1,009.33	996.00
(e)	Other Intangible assets	0.15	0.44	0.25
(f)	Intangible assets under development		-	0.23
(g)	Biological Assets other than bearer plants	_	* •	_
(h)	Financial assets			2 0
	(i) Investments	8.95	3.96	4.05
	(ii) Trade Receivables	-		_
	(iii) Loans	-	, s	-
	(iv) Other non-current financial assets	5.44	5.93	5.44
(i)	Deferred tax assets (net)	291.29	283.63	291.29
(j)	Advance income tax (net)	- 1		* - *
(k)	Other non-current assets	-		<u>-</u>
	S	8 I 8 I		
2	Current Assets		71	
(a)	Inventories	31.67	36.53	40.69
(b)	Financial assets	×5		
	(i) Investments	- 1		-
	(ii) Trade Receivables	348.23	472.51	404.43
	(iii) Cash and cash equivalents	4.61	2.85	1.86
ш	(iv) Bank balances other than above	1.04	16.34	1.04
	(v) Loans	2.33	3.24	2.61
	(vi) Others financial assets	-	-	-
(c)	Current tax assets (Net)	14.79	24.54	21.79
(d)	Other current assets	108.94	88.42	102.90
(e)	Assets classified as held for sale	380.27		380.27
	TOTAL - ASSETS	2,255.44	2,569.86	2,316.68
В	EQUITY AND LIABILITIES			
1	Equity			
(a)	Equity share capital	850.49	050.40	050.40
(b)	Other equity	1.97	850.49 152.96	850.49
2	Liabilities	1.97	152.96	14.72
(I)	Non-current liabilities	1		
	Financial liabilities			
(α)	(i) Borrowings	845.76	1 000 54	007.00
	(ii) Trade Payables	045.76	1,026.54	837.89
	(iii) Other financial liabilities	-	-	-
(b)	Provisions	4.00	-	-
, ,	Deferred tax liabilities (Net)	1.33	- 1	1.33
(d)	Other non - current liabilities	-	-	-
(u)	Other fion - Current habilities	- "	-	-
(II)	Current liabilities	B		
75 A TO ST. 11	Financial liabilities			
` '	(i) Borrowings	194.33	151.59	350.96
	(ii) Trade payables	229.38	114.72	129.32
	(iii) Other current financial liabilities	92.77	245.37	99.44
	Other current liabilities	39.24	28.19	32.36
, ,	Short-term provisions	0.17	20.19	0.17
	Current tax liabilities (net)	3.17		0.17
	Other non - current liabilities			- F -
	TOTAL EQUITY AND LIABILITIES	2,255.44	2,569.86	2,316.68
				_,0 10

Mumbai a

By Order of the Board For Parnax Lab Limited

Prakash M Shah Whole Time Director & CEO DIN NO: 00440980

Mumbai Date : 14-11-2018

LADHA SINGHAL & ASSOCIATES

CHARTERED ACCOUNTANTS

To
The Board of Directors,
Parnax Lab Limited,
114, Building No. 8,
Jogani Industrial Complex,
Chunabhatti, Mumbai – 400 022

- (i) We have reviewed the unaudited consolidated financial results of Parnax Lab Limited("the Parent") and its Subsidiary; Naxpar Pharma Private Limited ("the Subsidiary"), for the quarter and six month ended September 30, 2018 which are included in the accompanying "Statement of Unaudited Consolidated Financial Results for the quarter and six month ended September 30, 2018" together with the relevant notes thereon ("the Statement'). The Statement has been prepared by the Parent pursuant to Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015") read with SEBI Circular No. CIR/CFD/FAC/62/2016dated July 05, 2016. The Statement is the responsibility of the Parent's Management and has been approved by the Board of Directors. The Statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other recognized accounting practices and policies. Our responsibility is to issue a report on the Statement based on our review.
- (ii) We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Parent's personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
- (iii) Based on our review conducted as stated above, nothing has come to our attention that cause us to believe that the accompanying Statement has not been prepared in all material respects in accordance with Ind AS and other recognized accounting practices and policies and has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ladha Singhal and Associates

Chartered Accountants

(FRN: 120241W)

(Vinod Ladha)

Partner M. No. 104151

Place: Mumbai

Dated:14th November, 2018

TERED AC

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022. Tel: 022 - 3001 5666, Fax: 2405 7708, Email: info@naxparlab.com, Website: www.naxparlab.com

CIN:-L36912MH1982PLC027925

STATEMENT OF CONSOLIDATED FINANCIAL DESILITS FOR THE OLIAPTED & HALF YEAR ENDED 20 00 2010

Unaudited Correspondin g Half Year Ended	Audited Current Ye Ended
30.09.2017	31.03.2018
5,829.79	10,549
30.80	134
5,860.59	10,684
3,172,44	5,443
	70
(110.38)	(24
538.32	1,167
	434
	374
	2,792
1,512.51	123
5.553.88	10,381
	302
-	
306.71	302
n	150
n	48
Ŭ	(1
306.71	105
	C
	105
000.01	
	1 :
	·
306.71	108
	<u> </u>
207.04	400
	105
0.80	(
-	
	2
	(
205.04	108
0.80	708
	// K
850.49	// 85
٠	30.80 5,860.59 3,172.44 42.27 (110.38) 538.32 217.09 181.80 1,512.34 5,553.88 306.71 0 0 306.71 0.80 305.91

(2) Diluted

4.89

0.85

3.43

1.24 Mumba 1.24

5.74

3.61

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 14, 2018
- The Statutory Auditors have carried out a Limited Review of the above financial results of the Company for the quarter and half year ended September 30, 2018
- 3 EPS for quarter ended is on non annualised basis.
- 4 The Company is dealing into one segment : Dealing in Pharmaceutical Formulations
- 5 Figures pertaining to previous period/year have been re-grouped, re-classified and restated wherever found necessary.

Place : Mumbai Date : 14-11-2018



By Order of the Board For Parnax Lab Limited

Prakash M Shah Whole Time Director & CEO

DIN NO: 00440980

GALA NO. 114, BLDG. NO. 8, JOGANI INDUSTRIAL COMPLEX, CHUNABHATTI, MUMBAI 400022. Tel: 022 - 3001 5666, Fax: 2405 7708, Email: info@naxparlab.com, Website: www.naxparlab.com CIN:-L36912MH1982PLC027925

Statement of Consolidated Assets and Liabilities as at 30.09.2018

(Rs. in Lacs)

		Consolidated		
	-	Unaudited	Audited	
S. No.	Particulars	30.09.2018	Unaudited 30.09.2017	31.03.2018
A	ASSETS			
1	Non-Current Assets			
(a)	Property, plant and equipment	4,396.82	4,845.27	4,348.47
(b)	Capital work-in-progress	272.22		-
(c)	Investment Property			-
(d)	Other Intangible assets	21.83	15.50	21.53
(e)	Financial assets		-	
	(i) Investments	28.22	34.18	23.33
	(ii) Other non-current financial assets	39.95	42.22	35.60
(f)	Deferred tax assets (net)	-		-
(g)	Other non-current assets	667.28	662.00	662.00
2	Current Assets			
(a)	Inventories	689.55	748.62	767.38
(b)	Financial assets			
	(i) Investments			
	(ii) Trade Receivables	2,136.05	1,854.61	1,866.36
	(iii) Cash and cash equivalents	37.52	15.30	95.93
	(iv) Bank balances other than above	121.75	71.44	64.64
	(v) Loans	66.57	46.32	63.81
(c)	Current tax assets (Net)	110.29	149.17	73.78
	Other current assets	409.09	246.19	334.25
	Assets classified as held for sale	380.27	2 10.10	380.27
	TOTAL - ASSETS	9,377.41	8,730.82	8,737.35
В	EQUITY AND LIABILITIES			
1	Equity			
(a)	Equity share capital	850.49	850.49	850.49
(b)	Other equity	2,887.93	2,592.34	2,400.67
	Equity attributable to owner	3,738.42	3,442.83	3,251.16
	Non Controlling Interest	8.04	7.15	7.04
	Total Equity	3,746.46	3,449.98	3,258.20
2	Liabilities			
(1)	Non-current liabilities			
(a)	Financial liabilities			
EX.	(i) Borrowings	1,848.87	2,350.33	1,669.49
(b)	Provisions	23.06	_,=====================================	23.06
(c)	Deferred tax liabilities (Net)	67.53	19.44	67.53
(d)	Other non - current liabilities			-
(II)	Current liabilities			
(a)	Financial liabilities			
	(i) Borrowings	1,225.52	1,550.97	1,502.87
	(ii) Trade payables	975.24	507.40	767.60
22	(iii) Other current financial liabilities	1,276.71	757.70	1,288.99
	Other current liabilities	211.90	82.28	157.50
(c)	Short-term provisions	2.12	12.72	2.11
	Total Liability	5,630.95	5,280.84	5,479.15
	TOTAL EQUITY AND LIABILITIES	9,377.41	8,730.82	8,737.35

Mumbai

Date: 14-11-2018

By Order of the Board For Parnax Lab Limited

Prakash M Shah Whole Time Director & CEO DIN NO: 00440980